Compare Lumen Technologies Inc (LUMN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs BIO-TECHNE Corp — how do they compare? Lumen Technologies Inc trades at $6.32 (market cap $6.85B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | TECH | |
|---|---|---|
Market Cap | $6.85B | $11.24B |
Sector | Media | Health |
52-Week High | $11.83 | $72.29 |
52-Week Low | $3.74 | $43.31 |
Enterprise Value | $18.47B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.24, up 5.76% in the last session, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -8.65% and ROE of -78.94%, though Q2 2026 earnings beat estimates with a narrower loss. Strategic revenue growth of 14.1% highlights progress in digital transformation, but high debt of $17.49 billion remains a concern. Recent CEO share purchases and analyst downgrades reflect conflicting sentiment.
The outlook is cautious due to persistent losses and heavy debt, offset by potential from digital initiatives. Investment opportunity lies in successful execution of the transformation strategy, but risks include revenue declines and interest burdens. Analysts maintain a neutral stance with a $7.38 price target, suggesting limited upside from current levels amid operational challenges.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
